The Asthma Quality of Life Questionnaire (AQLQ) Validation of a Standardized Version of the Asthma Quality of Life Questionnaire*
|
|
- Alexia Parks
- 5 years ago
- Views:
Transcription
1 Validation of a Standardized Version of the Asthma Quality of Life Questionnaire* Elizabeth F. Juniper, MSc; A. Sonia Buist, MD; Fred M. Cox, PhD; Penelope J. Ferrie, BA; and Derek R. King, BMath Background: In the original 32-item Asthma Quality of Life Questionnaire (AQLQ), five activity questions are selected by patients themselves. However, for long-term studies and large clinical trials, generic activities may be more appropriate. Methods: For the standardized version of the AQLQ, the AQLQ(S), we formulated five generic activities (strenuous exercise, moderate exercise, work-related activities, social activities, and sleep) to replace the five patient-specific activities in the AQLQ. In a 9-week observational study, we compared the AQLQ with the AQLQ(S) and examined their measurement properties. Forty symptomatic adult asthma patients completed the AQLQ(S), the AQLQ, the Medical Outcomes Survey Short Form 36, the Asthma Control Questionnaire, and spirometry at baseline, 1, 5, and 9 weeks. Results: Activity domain scores (mean SD) were lower with the AQLQ ( ) than with the AQLQ(S) ( ; p ) and correlation between the two was moderate (r 0.77). However, for overall scores, there was minimal difference (AQLQ, ; AQLQ(S), ; r 0.99). Reliability (AQLQ intraclass correlation coefficient, 0.95; AQLQ(S) intraclass correlation coefficient, 0.96) and responsiveness (AQLQ, p < ; AQLQ(S), p < ) were similar for the two instruments. Construct validity (correlation with other measures of health status and clinical asthma) was also similar for the two instruments. Conclusions: The AQLQ(S) has strong measurement properties and is valid for measuring health-related quality of life in asthma. The choice of instrument should depend on the task at hand. (CHEST 1999; 115: ) Key words: asthma; health-related quality of life; questionnaire Abbreviations: ACQ asthma control questionnaire; AQLQ Asthma Quality of Life Questionnaire; AQLQ(S) standardized version of the AQLQ; ICC intraclass correlation coefficient; PEF peak expiratory flow; SF-36 Medical Outcomes Survey Short Form 36 The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the problems that adults with asthma experience in their day-to-day lives. 1 Six independent studies have shown that it has strong measurement properties both as an evaluative and as a discriminative instrument. 2 7 A feature of the AQLQ is that 5 of the 11 activity questions are selected by patients themselves. Many clinicians and investigators *From the Department of Clinical Epidemiology and Biostatistics (Prof. Juniper, Ms. Ferrie, and Mr. King), McMaster University, Hamilton, Ontario, Canada; Oregon Health Sciences University (Dr. Buist), Portland, OR; and Glaxo Wellcome Inc (Dr. Cox), Research Triangle Park, NC. Supported by a grant from Glaxo Wellcome Inc. Manuscript received August 26, 1998; revision accepted December 29, Correspondence to: Elizabeth Juniper, MSc, Department of Clinical Epidemiology and Biostatistics, McMaster University Medical Centre, 1200 Main St West, Hamilton, Ontario, L8N 3Z5, Canada; juniper@fhs.mcmaster.ca consider that this attribute enhances content validity, accommodates cultural differences, and improves relevance in clinical practice. 8,9 However, for some studies in which this feature is less important, generic activities may be more appropriate. For instance, in long-term clinical trials and patient monitoring, patients activities may change over time, and in large clinical trials, the ease and convenience of standardized questions may outweigh the benefits of individualized questions. In addition, for cross-sectional surveys in which one is comparing burden of illness between individual patients or groups of patients, standardized questions are usually considered preferable. We have developed a standardized version of the AQLQ, the AQLQ(S), in which five generic activities replace the five patient-specific activities of the AQLQ. In this validation study, we have compared scores generated by the AQLQ and AQLQ(S) and CHEST / 115 / 5/ MAY,
2 have examined the measurement properties that are important for the confident use of the AQLQ(S) in clinical trials, clinical practice, and cross-sectional surveys. Materials and Methods Formulation of the Five Generic Activities Our aim was to formulate five generic activity questions that would cover the activities that are most frequently identified by asthma patients as being the most troublesome in their day-today lives. In addition, we wanted to ensure that the balance of the five questions (physical, social, occupational) reflects the frequency with which the activities are identified by patients. We reviewed the original item reduction data from the development of the AQLQ 1 and a number of clinical trial databases in which the AQLQ had been an outcome. From these, we formulated five questions that we considered met the criteria identified above, and we grouped them according to quality-of-life function 10 (Table 1). The wording of the five generic activity questions was pretested in 10 asthma patients to ensure ease and accuracy of understanding. Validation Study Subjects: Forty adults (18 to 65 years old) with current symptoms of asthma were enrolled from among patients who had participated in previous research studies and from among respondents to notices in the local media. Subjects were excluded if they had an illness, other than asthma, that might have an impact on health-related quality of life or if they had evidence of fixed airway obstruction (FEV 1 after bronchodilator 60% predicted). All participants understood the English version of the AQLQ and were able to make reliable measurements of peak expiratory flow (PEF). They all signed a consent form that had been approved by the McMaster University Faculty of Health Sciences Ethics Committee. Study Design: In this 9-week observational study, patients were assessed at baseline and after 1, 5, and 9 weeks. At each clinic visit, spirometry was measured and the following questionnaires were completed: the self-administered version of the AQLQ plus the five new generic activity questions, the Asthma Control Questionnaire (ACQ), 11 and the Medical Outcomes Survey Short Form 36 (SF-36). 12 For 1 week before each follow-up clinic visit, patients completed a daily diary. Patients whose asthma was adequately controlled continued taking their established asthma medications throughout the study. Asthma was considered adequately controlled when Table 1 Five Generic Activities Strenuous activities (such as hurrying, exercising, running up stairs, sports) Moderate activities (such as walking, housework, gardening, shopping, climbing stairs) Social activities (such as talking, playing with pets/children, visiting friends/relatives) Work-related activities* (tasks that you have to do at work) Sleeping *If you are not employed or self-employed, these should be tasks you have to do most days. none of the following were present: awoken at night by symptoms, persistent waking in the morning with symptoms, limitation of normal daily activities, sputum, inhaled shortacting 2 -agonist 2 puffs daily, or FEV 1 after bronchodilator 70% predicted. Patients whose asthma was not adequately controlled at week 1 or week 5 were advised to increase their dosage of medication in the manner recommended by their asthma consultant. For those without a treatment plan, we recommended an inhaled steroid, beclomethasone dipropionate, up to 800 g daily. Outcome Measures With AQLQ Plus Five Generic Activities: The AQLQ 1 has 32 questions, the first 5 of which are the patient-specific activities. At the first clinic visit, each patient selects the five activities in which he or she has been most troubled by asthma during the previous 2 weeks. These activities are retained throughout the study. For this study, we used the self-administered version of the AQLQ, and the five generic activity questions were added to the end of the questionnaire. Patients respond to each question on a seven-point scale and recall their experiences during the previous 2 weeks. Results are expressed as four domain scores (symptoms, 12 questions; activities, 11 questions; emotional function, 5 questions; and environmental exposure, 4 questions) and as an overall score (32 questions). Outcome Measures With ACQ: Ninety-two asthma clinicians from around the world identified the symptoms that are most important in determining clinical asthma control. The ACQ contains the five top-scoring symptoms, a question about 2 - agonist use, and another about the FEV 1 percent predicted (total of seven questions). The ACQ has been validated and shows strong measurement properties. 11 Outcome Measures With Daily Diary: Each morning patients recorded the best prebronchodilator PEF of three blows and the amount of short-acting 2 -agonist used in the previous 24 h. Outcome Measures With SF-36: This 36-item generic health status questionnaire provides summary scores for physical and mental health. In patients with asthma, it has good internal consistency and cross-sectional validity. 12 Statistical Analysis First, we examined concordance between the AQLQ(S) and the AQLQ (criterion validity). Using data from the first clinic visit, we evaluated differences between AQLQ and AQLQ(S) with a paired t test and examined the closeness of association with a Pearson correlation coefficient. Second, we compared the measurement properties of the two instruments. These included the following: (1) reliability, the ability of the instrument to give reproducible results when the clinical state is stable and to discriminate between patients with different levels of impairment; (2) responsiveness, the ability of the instrument to detect changes in clinical status even if that change is small; (3) cross-sectional validity, observed differences between patients truly reflect differences in asthma-specific quality of life (demonstrated by showing that correlations between both the AQLQ and the AQLQ(S) and other measures of asthma and generic health status are close to expected); and (4) longitudinal validity, observed changes in score with time truly represent changes in asthma-specific quality of life (demonstrated by showing that changes in AQLQ and AQLQ(S) scores correlate in a predictable manner with changes in other measures of health status). 13 This analysis required that we categorize patients according to whether their asthma remained stable between consecutive visits (weeks 1 to 5 and weeks 5 to 9) or whether it changed. 14 Categorization was performed using data from the ACQ in which a change in score 0.5 on the seven-point scale can be considered clinically important. 11 Pa Clinical Investigations
3 tients whose conditions either improved or deteriorated by a score 0.5 were placed in the changed group. All other patients were placed in the stable group. Reliability of the instruments was determined from patients in the stable group. If a patient was in stable condition between both weeks 1 and 5 and between weeks 5 and 9, a single observation was selected blindly using a random number generator. Reliability has been estimated as the within-subject SD and related to the total SD as an intraclass correlation coefficient (ICC). This statistic not only provides evidence of the instrument s ability to give reproducible results but also its ability to discriminate between patients with different levels of impairment (1 perfect reliability, 0 no reliability). 13 Responsiveness was determined in three ways. First, for patients in the changed group, we determined whether the instruments could detect these changes using a paired t test. Second, we determined whether the instruments could detect differences between the stable and changed groups using an unpaired t test. For both estimations, data from those whose conditions deteriorated and those whose conditions improved were combined by changing the sign of those whose conditions deteriorated after it had been shown that improvements and deteriorations in the patients in this study were symmetric. Third, we calculated the responsiveness index for each questionnaire. This index provides evidence of the degree of responsiveness of the instrument and is calculated by dividing change scores by the pooled SD of change. 15 The difference in responsiveness indices was tested using a paired t test. Some patients contributed two observations to a group. To ensure that this did not result in an overestimate of the precision of responsiveness, we inflated (multiplied) the variance to take into account within-subject correlations by the quantity 1 (n 1), where is the ICC of the change scores and n 2 (the number of observations per subject). 16 Results All 40 patients completed the first three assessments; 1 patient failed to return for the final visit. Demographic data are shown in Table 2. Comparison of Instruments The activities that patients selected most frequently for the patient-specific questions of the Table 3 Patient-Specific Activities Chosen by Three or More Patients (AQLQ) Activity No. of Patients Walking/going for a walk 13 Running uphill/upstairs 13 Housework 11 Hurrying 10 Carrying out activities at work 10 Exercising/playing sports 10 Walking uphill/upstairs 10 Sleeping 9 Jogging/running 8 Bicycling 8 Talking 6 Social activities/visiting friends 6 Playing with pets 5 Playing with children 4 Laughing 4 Gardening 4 Sexual intercourse 4 Home maintenance 3 Singing 3 Dancing 3 AQLQ are shown in Table 3. As may be seen, all of these activities are well covered by the five generic activities of the AQLQ(S) (Table 1), and the balance of physical, social, and occupational activities in the generic questions is good. The mean activity domain score was lower with the AQLQ ( ) than with the AQLQ(S) ( ), in which 7 no impairment and 1 maximum impairment. Although the mean difference between the two instruments was small, it still reached statistical significance (p ). As a result, the overall quality-of-life score (mean SD) was slightly lower with the AQLQ ( ) than with the AQLQ(S) ( ), and this too reached significance (p ). Correlation between the two activity domains was 0.77, but this made little difference to the overall correlation between the AQLQ and the AQLQ(S) (r 0.99). Table 2 Patient Characteristics at Baseline* Patient Characteristics Baseline Values No. of patients 40 Age, yr 38.4 (11.2) Sex, M/F 12/28 Current asthma medications No medications 1 Bronchodilators alone 7 Bronchodilators inhaled steroids 29 Bronchodilators inhaled steroids salmeterol 3 FEV 1 % predicted before bronchodilator 77.8 (20.2) ACQ 1.65 (0.74) *Data given as mean (SD). M male; F female. Medications used in the previous 30 days. Table 4 Reliability of the AQLQ and the AQLQ(S) (n 35)* Instrument Within- Subject SD Between- Subject SD ICC Original AQLQ overall Symptoms Environment Emotions Activities AQLQ(S) overall Activities *The symptom, environmental stimuli, and emotional function domains are identical in the AQLQ and the AQLQ(S). CHEST / 115 / 5/ MAY,
4 Table 5 Responsiveness Expressed as the Change in Score Between Consecutive Visits* Instrument Patients Who Were in Stable Condition Between Visits (n 44) Patients Who Changed Between Visits (n 35) Difference Between Stable and Changed, p Value Original AQLQ overall 0.08 (0.37) 0.89 (0.66) Symptoms 0.11 (0.54) 1.27 (0.78) Environment 0.01 (0.64) 0.45 (0.81) Emotions 0.05 (0.65) 0.88 (1.06) Activities 0.10 (0.40) 0.61 (0.58) AQLQ(S) overall 0.08 (0.35) 0.87 (0.60) Activities 0.09 (0.35) 0.60 (0.52) *The symptom, environmental stimuli, and emotional function domains are identical in the AQLQ and the AQLQ(S). Values given as mean (SD) unless otherwise indicated. p p Measurement Properties Reliability: Thirty-five patients remained in stable condition between two consecutive clinic visits and thus contributed to the reliability analysis. The within-subject SDs and ICCs for overall scores and individual domains are shown in Table 4. In summary, the reliability of the AQLQ and the AQLQ(S) was very similar both for overall score and for the activity limitation domain. Responsiveness: Twenty-six patients contributed 35 observations to the changed group; 35 patients contributed 44 observations to the stable group. Table 5 shows that responsiveness was strong in both instruments. They were both able to detect the within-subject changes in the changed group and to differentiate between the stable and changed groups. The responsiveness indices for the two instruments were very similar (AQLQ, 1.35; AQLQ(S), 1.34), and the difference was not significant (p 0.35). Construct Validity: Both cross-sectional and longitudinal correlations are sufficiently similar for the AQLQ and the AQLQ(S) (Tables 6 and 7) for us to have confidence that the AQLQ(S) is measuring the same construct as the AQLQ. Discussion The results of this study provide evidence that the AQLQ(S) is a valid instrument for measuring healthrelated quality of life in adults with asthma. We evaluated validity in two ways: first, by determining the level of concordance (agreement) between the AQLQ(S) and the AQLQ (criterion validity); and, second, by comparing the measurement properties of the two instruments (construct validity). The concordance analysis showed that the mean score for the activity domain of the AQLQ(S) was significantly higher (ie, less limitation) than for the activity domain of the AQLQ and that the correlation between the two activity domains was only This lack of concordance is not surprising because patients select the activities that are most troublesome for the AQLQ and these activities may not all be captured by the generic activities in the AQLQ(S). In addition, one or more of the generic activities may be totally irrelevant to an individual patient (eg, a patient who never does any strenuous exercise). Although it is important to be aware of these differences between the two instruments, the mean dif- Table 6 Cross-Sectional Validity* Instrument ACQ PEF FEV 1,% predicted 2 -Agonist Use Physical SF-36 Mental AQLQ overall Symptoms Environment Emotions Activities AQLQ(S) overall Activities *The symptom, environmental stimuli, and emotional function domains are identical in the AQLQ and the AQLQ(S). Correlations are presented as positive whenever the association between the two variables is consistent with validity. Pearson correlation coefficients were used (n 40) Clinical Investigations
5 Table 7 Longitudinal Validity* Instrument ACQ PEF FEV 1,% predicted 2 -Agonist Use Physical SF-36 Mental AQLQ overall Symptoms Environment Emotions Activities AQLQ(S) overall* Activities *The symptom, environmental stimuli, and emotional function domains are identical in the AQLQ and the AQLQ(S). Correlations are presented as positive whenever the association between the two variables is consistent with validity. Pearson correlation coefficients were used (n 40). ference for the overall score between the AQLQ and the AQLQ(S) was 0.1 and for the activity domain it was 0.2, both of which are considerably less than the minimal important difference of and probably not of clinical importance. The second part of the analysis provided evidence that the measurement properties of the AQLQ(S) and the AQLQ (reliability, responsiveness, and both cross-sectional and longitudinal validity) are very similar and add further support for the validity of the AQLQ(S). The correlations between both the AQLQ and the AQLQ(S) and other measures of clinical asthma status are very similar to those observed in a large number of other studies. 2 7,11,16 They emphasize that within an individual patient, the problems and impairments that the patient experiences as a result of asthma cannot be inferred from the clinical measures of airway function; they have to be measured directly. A limitation of this study is the relatively small sample size. However, other validation studies of the AQLQ would suggest that the sample size is quite adequate. 2 4 In addition, patients may have been homogeneous. Although we tried to ensure that patients represented a wide range of asthma severity, age, and sex, the study was conducted in southern Ontario where the majority of patients are Caucasians. Testing of the AQLQ(S) in other settings will increase our confidence in the ability to generalize these results. When selecting an instrument, it is important to review which properties are most important for the task at hand. There is no doubt that the patientspecific activities in the original AQLQ allow assessment of the problems that are important to the individual patient, and therefore this instrument can be considered to have better content validity than the AQLQ(S). This may be important if the instrument is being used in clinical practice to identify individual patient problems and the effect of interventions on these problems. It has also been suggested that patient-specific questions help to overcome cultural, climatic, and ethnic differences. 8,9 In this study, we compared only the English versions of the AQLQ and the AQLQ(S), and further studies should be conducted to confirm the finding in other languages. If the aim of a study is to compare burden of illness in a cross-sectional survey, the AQLQ(S) is probably better suited than the AQLQ. Although the discriminative properties of the AQLQ are strong and the patient-specific activities are only 5 of the 11 activity questions, individualized questions mean that the types and strenuousness of activities vary between patients. The AQLQ(S) is also probably more appropriate than the AQLQ for long-term ( 1 year) clinical trials, cohort studies, and monitoring, when patients activities and priorities may change with time. For shorter periods, the decision becomes more difficult, and it is for each investigator to decide which priorities are more important. Responsiveness data from the two instruments are very similar, and, therefore, sample sizes for the AQLQ(S) (both parallel-group and crossover studies) will be very similar to those required for the AQLQ. 2 Although it is more time-consuming to elicit patient-specific activities, the inclusion of these questions enables patients to feel that things that are important to them are being taken into consideration, and this may enhance compliance. Most of these advantages and disadvantages are only speculative. Until further studies can provide evidence of the strengths and weaknesses of the two instruments in different clinical settings, the choice must rest on the individual clinician or investigator. References 1 Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: devel- CHEST / 115 / 5/ MAY,
6 opment of a questionnaire for use in clinical trials. Thorax 1992; 47: Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147: Rutten-van Molken MPMH, Clusters F, Van Doorslaer EKA, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995; 8: Rowe BH, Oxman AD. Performance of an asthma quality of life questionnaire in an outpatient setting. Am Rev Respir Dis 1993; 148: Leidy NK, Coughlin C. Psychometric performance of the Asthma Quality of Life Questionnaire in a US sample. Qual Life Res 1998; 7: Sanjuas C, Alonso J, Sanchis J, et al. The quality of life questionnaire with asthma patients: the Spanish version of the Asthma Quality of Life Questionnaire. Arch Bronconeumol 1995; 31: Apter AJ, Reisine ST, Affleck G, et al. The influence of demographic and socioeconomic factors on health-related quality of life in asthma. J Allergy Clin Immunol 1999; 103: McGee H, O Boyle CH, Hickey A, et al. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med 1991; 21: O Boyle CA, McGee H, Hickey A, et al. Individual quality of life in patients undergoing hip replacement. Lancet 1992; 339: Schipper H, Clinch J, Powell V. Definitions and conceptual issues. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott-Raven Publishers, 1996; Juniper EF, O Byrne PM, Guyatt GH, et al. Development and validation of the Asthma Control Questionnaire [abstract]. Am J Respir Crit Care Med 1998; 157:A Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma: 1. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 1994; 149: Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties? J Clin Epidemiol 1992; 45: Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new quality of life instrument. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. New York: Raven Press, 1995; Guyatt GH, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987; 40: Juniper EF, Guyatt GH, Feeny DH, et al. Minimum skills required by children to complete health-related quality of life instruments: comparison of instruments for measuring asthma-specific quality of life. Eur Respir J 1997; 10: Clinical Investigations
Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma
Eur Respir J 2001; 18: 38 44 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Comparison of the standard gamble, rating scale, AQLQ and SF-36
More informationValidation of the Asthma Quality of Life Questionnaire (AQLQ UK English Version) in Indian Asthmatic Subjects
ORIGINAL ARTICLE Validation of the Asthma Quality of Life Questionnaire (AQLQ UK English Version) in Indian Asthmatic Subjects Sunil K. Chhabra and Shivu Kaushik Department of Cardiorespiratory Physiology,
More informationDevelopment and validation of a questionnaire to measure asthma control
Eur Respir J 1999; 14: 902±907 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Development and validation of a questionnaire to measure
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationDevelopment of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)
954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and
More informationAchieving guideline-based asthma control: does the patient benefit?
Eur Respir J ; : 88 9 DOI:.8/99..97 Printed in UK all rights reserved Copyright #ERS Journals Ltd European Respiratory Journal ISSN 9-9 Achieving guideline-based asthma control: does the patient benefit?
More informationAsthma quality of life during 1 year of treatment with budesonide with or without formoterol
Eur Respir J 1999; 14: 1038±1043 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Asthma quality of life during 1 year of treatment with
More informationInterpreting thresholds for a clinically significant change in health status in asthma and COPD
Eur Respir J 2002; 19: 398 404 DOI: 10.1183/09031936.02.00063702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Interpreting thresholds for
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationAccuracy of Parental and Child s Reports of Changes in Symptoms of Childhood Asthma
7. Cecka JM, Gjertson DW, Terasaki PI. Pediatric renal transplantation - a review of the UNOS data. Pediatr Transplant 1997; 1: 55-64. 8. Alexander SR. Pediatric end stage renal disease. Am J Kidney Dis
More informationSect Respir Sys Foreign Med Sci,J un. 2004,Vol. 24,Suppl
2004 6 24 Sect Respir Sys Foreign Med Sci,J un. 2004,Vol. 24,Suppl 65,,1989 2002 280, 14,, ; ;, 2 2 1949, W HO,,,,,,,, 1 1. 1 ( ast hma quality of life questio nnaire,aql Q) 1. 1. 1 AQL Q J uniper : 152,,5,
More informationValidation of an asthma quality of life diary in a
724 Thorax 1995;50:724-730 Validation of an asthma quality of life diary in a clinical trial M E Hyland, G R Crocker Department of Psychology M E Hyland School of Mathematics and Statistics G R Crocker
More informationA Survey on the Quality of Life in Patients with Bronchial Asthma in an Outpatient Clinic in Malaysia
British Journal of Medicine & Medical Research 4(5): 1187-1194, 2014 SCIENCEDOMAIN international www.sciencedomain.org A Survey on the Quality of Life in Patients with Bronchial Asthma in an Outpatient
More informationDevelopment and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire*
Original Research COPD Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Makiko Meguro, Mphil; Elizabeth A. Barley, PhD, CPsychol; Sally Spencer,
More informationREVIEW Key points Assessing asthma quality of life: its role in clinical practice Educational aims Correspondence: Summary 193
Key points Asthma patients want help to improve their ability to function in their daily lives (physical, social, occupational and emotional). Awareness of patients problems and a willingness to treat
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationAn 18-item standardized Asthma Quality of Life Questionnaire-AQLQ(S)
Qual Life Res (2008) 17:323 332 DOI 10.1007/s11136-007-9297-y An 18-item standardized Asthma Quality of Life Questionnaire-AQLQ(S) Eirini Grammatopoulou Æ Emmanouil Skordilis Æ Dimitra Koutsouki Æ George
More informationP revalence surveys have estimated that 4% of middle aged
483 ORIGINAL ARTICLE Independent validation of the Sleep Apnoea Quality of Life Index Y Lacasse, C Godbout, F Sériès... See end of article for authors affiliations... Correspondence to: Dr Y Lacasse, Centre
More informationPatient reported outcomes in respiratory diseases; How to assess clinical success in COPD
Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Thys van der Molen, University of Groningen, Department of General Practice, The Netherlands Mr Valette Smoking
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationPatient weighting of importance of asthma symptoms
138 Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD, UK L M Osman Health Economics Research Unit, University of Aberdeen, Aberdeen AB25 2ZD, UK L McKenzie J Cairns Respiratory
More informationComparing the Reliability of Asthma Control Instruments: Clinic Questionnaire versus Daily Diary
Comparing the Reliability of Asthma Control Instruments: Clinic Questionnaire versus Daily Diary EVA Y. OUANO-CRISOLOGO, MD, 1 MANUEL C. JORGE, MD, FPCCP 1 Objective: To determine if the Asthma Control
More informationPatient Assessment Quality of Life
Patient Assessment Quality of Life STEP 1 Learning objectives This module will provide you with an understanding of the importance of assessing Quality of Life (QoL) in patients and the role that quality
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationPSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA
St. George's Respiratory Questionnaire PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA Kwua-Yun Wang, Chi-Hue
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationCan the Asthma Control Questionnaire be used to differentiate between patients with controlled. uncontrolled asthma symptoms?
Ó The Author (2006). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org doi:10.1093/fampra/cml041 Family Practice Advance
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS
R2 (REVISED MANUSCRIPT BLUE 200208-877OC) ONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS Mario Castro, M.D., M.P.H. Nina A. Zimmermann R.N. Sue
More informationCanadian Expert Drug Advisory Committee Final Recommendation Plain Language Version
Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version MOMETASONE FUROATE/FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL (Zenhale Merck Canada Inc.) Indication: Asthma Maintenance
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationSpirometry and Flow Volume Measurements
Spirometry and Flow Volume Measurements Standards & Guidelines December 1998 To serve the public and guide the medical profession Revision Dates: December 1998 Approval Date: June 1998 Originating Committee:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFrequency of nocturnal symptoms in asthmatic children attending a hospital out-patient clinic
Eur Respir J, 1995, 8, 2076 2080 DOI: 10.1183/09031936.95.08122076 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Frequency of nocturnal
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationO bstructive sleep apnoea (OSA) clearly affects important
494 SLEEP A new standardised and self-administered quality of life questionnaire specific to obstructive sleep apnoea Y Lacasse, M-P Bureau, F Sériès... See end of article for authors affiliations... Correspondence
More informationAssociation of Asthma Control with Health Care Utilization and Quality of Life
Association of Asthma Control with Health Care Utilization and Quality of Life WILLIAM M. VOLLMER, LEONA E. MARKSON, ELIZABETH O CONNOR, LESLY L. SANOCKI, LESLYE FITTERMAN, MARC BERGER, and A. SONIA BUIST
More informationWest of Scotland Difficult Asthma Group Statement of Practice
West of Scotland Difficult Asthma Group Statement of Practice Member Health Boards: Ayrshire and Arran Dumfries and Galloway Forth Valley Lanarkshire Glasgow INFORMATION ON THE USE OF BRONCHIAL THERMOPLASTY
More informationCopyright General Practice Airways Group Reproduction Prohibited
Primary Care Respiratory Journal (2004) 13, 36 41 Evaluation of an intervention to improve successful completion of the Mini-AQLQ: comparison of postal and supervised completion Hilary Pinnock a, *, Aziz
More informationSYNOPSIS. Study centres This was a multicentre study conducted in 53 centres in Sweden.
Drug product: Symbicort Turbuhaler Drug substance(s): Budesonide/Formoterol Edition No.: 1 Study code: LD-039-0003 Date: 20 May 2005 SYNOPSIS An open, randomized, parallel group, multicentre, phase IIIB
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationDoes health-related quality of life in asthma patients correlate with the clinical indices?
Does health-related quality of life in asthma patients correlate with the clinical indices? Abstract Oni OA, MBBS, MSc, FMCP, Research Clinician McNeal PL, Florida, USA Erhabor GE, MBBS, FWACP, FRCP, Lecturer
More informationPoor adherence with inhaled corticosteroids for asthma:
Original Papers Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Milind P Sovani, Christopher I Whale, Janet Oborne, Sue Cooper,
More informationSymptoms, Quality of Life, and Health Service Contact among Young Adults with Mild Asthma
Symptoms, Quality of Life, and Health Service Contact among Young Adults with Mild Asthma LIESL M. OSMAN, CHRISTINE CALDER, ROMA ROBERTSON, JAMES A. R. FRIEND, JOSEPH S. LEGGE, and J. GRAHAM DOUGLAS Department
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationW e have shown in a previous meta-analysis of placebo
16 ASTHMA Clinical dose-response relationship of fluticasone propionate in adults with asthma M Masoli, M Weatherall, S Holt, R Beasley... See end of article for authors affiliations... Correspondence
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationPatient Reported Outcomes
Patient Reported Outcomes INTRODUCTION TO CLINICAL RESEARCH A TWO-WEEK INTENSIVE COURSE, 2010 Milo Puhan, MD, PhD, Associate Professor Key messages Patient-reported outcomes (PRO) is a broad group of outcomes
More informationPrimary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD
Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor
More informationAllwin Mercer Dr Andrew Zurek
Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack
More informationLEVEL ONE MODULE EXAM PART TWO [Reliability Coefficients CAPs & CATs Patient Reported Outcomes Assessments Disablement Model]
1. Which Model for intraclass correlation coefficients is used when the raters represent the only raters of interest for the reliability study? A. 1 B. 2 C. 3 D. 4 2. The form for intraclass correlation
More informationThis version is available from Sussex Research Online:
Validity of two common asthma-specific quality of life questionnaires: Juniper mini asthma quality of life questionnaire and Sydney asthma quality of life questionnaire Article (Published Version) Apfelbacher,
More informationAsthma and COPD Awareness
Asthma and COPD Awareness Molina Breathe with Ease sm and Chronic Obstructive Pulmonary Disease Molina Healthcare of Texas Summer 2013 Asthma Triggers You may not always know when an asthma attack will
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationInternational co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria.
Drug product: SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0681 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0681 Date: 24 Oktober, 2003 (For national
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationPsychometric Evaluation of Self-Report Questionnaires - the development of a checklist
pr O C e 49C c, 1-- Le_ 5 e. _ P. ibt_166' (A,-) e-r e.),s IsONI 53 5-6b
More informationRelationship between guideline treatment and health-related quality of life in asthma
Eur Respir J 2004; 23: 718 722 DOI: 10.1183/09031936.04.00065204 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 Relationship between guideline
More informationValidation of the Asthma Quality of Life Questionnaire With Momentary Assessments of Symptoms and Functional Limitations in Patient Daily Life
Validation of the Asthma Quality of Life Questionnaire With Momentary Assessments of Symptoms and Functional Limitations in Patient Daily Life Robin S Everhart MSc, Joshua M Smyth PhD, Alecia M Santuzzi
More informationAsthma Control Test and Asthma Quality of Life Questionnaire Association in Adults
ORIGINAL ARTICLE Iran J Allergy Asthma Immunol December 2012; 11(4): 301-307 Asthma Control Test and Asthma Quality of Life Questionnaire Association in Adults Aylin Ozgen Alpaydin 1, Mine Bora 2, Arzu
More informationAsthma Assessment & Review
ASTHMA RESOURCE PACK Section 5B Asthma Assessment & Review In this section: 1. Primary Care initial assessment and review Asthma Resource Pack Section 5B: Asthma Assessment & Review Version 3.0 Last Updated:
More informationTARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS
TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationGuideline adherence for the treatment of asthma in general practice is associated with a higher quality of life
Chapter 7 Guideline adherence for the treatment of asthma in general practice is associated with a higher quality of life Lisa G Pont, Thys van der Molen, Petra Denig, Ger Th van der Werf and Flora M Haaijer-Ruskamp
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationHealth care education, delivery, and quality
Relationships among quality of life, severity, and control measures in asthma: An evaluation using factor analysis Michael Schatz, MD, MS, a David Mosen, PhD, e Andrea J. Apter, MD, MSc, f Robert S. Zeiger,
More informationInternational Co-ordinating investigator None appointed.
Drug product: Budesonide/formoterol SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0673 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0673 Date: 13 June,
More informationAssessing health-related quality of life in asthma
QUALITY OF LIFE SYMPOSIUM Assessing health-related quality of life in asthma Elizabeth F Juniper MCSP MSc Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University
More informationAsthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives
Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives Camilla Boslev Bårnes MD and Charlotte Suppli Ulrik MD DMSc Introduction Methods Review of the Literature Adherence
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationCHAPTER 5. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma
CHAPTER 5 Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma Victor van der Meer, Henk F. van Stel, Moira J. Bakker, Albert C. Roldaan, Willem
More informationTreatment of acute asthmatic exacerbations with an increased dose of inhaled steroid
12 Paediatrics and Child Health, Dunedin School of Medicine, PO Box 913, University of Otago Medical School, Dunedin, New Zealand J Garrett Preventive and Social Medicine, Dunedin School of Medicine S
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationPeak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics
ORIGINAL ARTICLE Peak Expiratory Flow Variability Adjusted by Forced Expiratory Volume in One Second is a Good Index for Airway Responsiveness in Asthmatics Kazuto Matsunaga, Masae Kanda, Atsushi Hayata,
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationSubject: Bronchial Thermoplasty
Subject: Bronchial Thermoplasty Guidance Number: MCG-171 Revision Date(s): Original Effective Date: 6/12/14 Medical Coverage Guidance Approval Date: 6/12/14 PREFACE This Medical Guidance is intended to
More informationA comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD
RESPIRATORY MEDICINE (2001) 95, 71 77 doi:10.1053/rmed.2000.0976, available online at http://www.idealibrary.com on A comparison of three disease-specific and two generic health-status measures to evaluate
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationThe anti-ige antibody omalizumab improves asthma-related quality of life in patients with allergic asthma
Eur Respir J 22; 2: 188 194 DOI: 1.1183/931936.2.1652 Printed in UK all rights reserved Copyright #ERS Journals Ltd 22 European Respiratory Journal ISSN 93-1936 The anti-ige antibody omalizumab improves
More informationReliability and validity of the International Spinal Cord Injury Basic Pain Data Set items as self-report measures
(2010) 48, 230 238 & 2010 International Society All rights reserved 1362-4393/10 $32.00 www.nature.com/sc ORIGINAL ARTICLE Reliability and validity of the International Injury Basic Pain Data Set items
More informationAsthma and Tobacco: Double Trouble for Wisconsin Adolescents
Asthma and Tobacco: Double Trouble for Wisconsin Adolescents Livia Navon, MS, RD; Beth Fiore, MS; Henry Anderson, MD ABSTRACT Background: Environmental tobacco smoke (ETS) exposure has been identified
More informationA sthma is the most common chronic disease of childhood
678 ORIGINAL ARTICLE Computerised paediatric asthma quality of life questionnaires in routine care H Mussaffi*, R Omer*, D Prais, M Mei-Zahav, T Weiss-Kasirer, Z Botzer, H Blau... Supplemental files 1
More informationReal-life Efficacy of Omalizumab After 9 Years of Follow-up
Brief Communication Allergy Asthma Immunol Res. 7 July;9(4):368-37. https://doi.org/.468/aair.7.9.4.368 pissn 9-7355 eissn 9-7363 Real-life Efficacy of Omalizumab After 9 Years of Follow-up Francesco Menzella,
More informationValidation of an Arabic Version of the ORWELL97 Questionnaire in Adults with Obesity
Validation of an Arabic Version of the ORWELL97 Questionnaire in Adults with Obesity Leila Itani 1, Simona Calugi 2, Dima Kriedieh 1, Germine El Kassas 1, Dana El Masri 1, Hana Tannir 1, Riccardo Della
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationASTHMA PROTOCOL CELLO
ASTHMA PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives, non medical and medical therapy and a scheme for inhaler dosage.
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationQUALITY OF LIFE AND MARKERS OF INFLAMMATION
NATIONAL INSTITUTE OF ENVIRONMENTAL MEDICINE DIVISION OF PHYSIOLOGY Karolinska Institutet, Stockholm, Sweden QUALITY OF LIFE AND MARKERS OF INFLAMMATION A STUDY OF ASTHMA IN PRIMARY CARE Per Olof Ehrs
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More information